Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024 Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been accelerated Challenging market environment and high fixed cost base led to weaker profitability.

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec HAMBURG, GERMANY / ACCESSWIRE / August 13, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progress of the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and programme-based achievements trigger payments of in total US$ 75 m to Evotec.

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / August 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE Reports First Half-year 2024 Results on 14 August 2024

Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just - Evotec Biologics with mid double-digit revenue growth versus strong comparable basis Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France Further strengthened sales order book in Discovery is basis for a moderate growth acceleration in H2 2024; conversion of orders into revenues taking longer than anticipated Reset towards sustainable profitable growth starts getting traction and will be enhanced to make Evotec more agile in a still challenging market environment HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has refined its guidance for the fiscal year 2024. For the current fiscal year, the Company expects Revenues1 in the range of € 790 - 820 m (low to mid-single-digit percentage growth vs previously low double-digit percentage growth; 2023: € 781.4 m); R&D expenditures are expected in a range of € 50 - 60 m (low double-digit percentage reduction vs previously mid-single to low double-digit percentage reduction; 2023: € 64.8 m); Adjusted EBITDA1 is expected to reach € 15 - 35 m (mid-double-digit percentage reduction vs previously mid double-digit percentage growth; 2023: € 66.4 m).

Evotec Provides Guidance Update

HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024. The Company expects Group revenues in the range of € 790 - 820 m (low to mid-single-digit percentage growth vs previously low double-digit percentage growth; 2023: € 781.4 m); R&D expenditures are expected in a range of € 50 - 60 m (low double-digit percentage reduction vs previously mid-single to low double-digit percentage reduction; 2023: € 64.8 m); Adjusted EBITDA is expected to reach € 15 - 35 m (mid double-digit percentage reduction vs previously mid double-digit percentage growth; 2023: € 66.4 m).

Evotec SE Provides Guidance Update

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.

Evotec and Pfizer Collaborate to Advance Drug Discovery in France

Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY and SEATTLE, WA / ACCESSWIRE / July 8, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced that its biologics segment, Just - Evotec Biologics, Inc., has expanded its strategic partnership with Sandoz. Just - Evotec Biologics will receive appropriate remuneration following early scientific validation, with further funding tied to achieving development milestones from 2025.

Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz

Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program Manufacturing Optimization Program effort enhances U.S. Government's rapid response capabilities for biologics MCMs in response to emergency situations HAMBURGSUND, SWEDEN / ACCESSWIRE / June 25, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., was selected by the U.S. Department of Defense ("DOD") to develop an accelerated monoclonal antibody ("mAb") development and manufacturing solution for the DOD's Manufacturing Optimization Program. The multi-year program award, valued up to $ 39 m, will support the U.S. Government's effort to enhance its rapid response capabilities for biologics medical countermeasures ("MCMs").

Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program

Bristol-Myers

Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / June 12, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.

Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb

Most agenda items adopted with great majority Annual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario Polywka HAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority. Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof.

Evotec SE: Results of the Annual General Meeting 2024

Evotec SE (NASDAQ:EVO ) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Company Participants Volker Braun - EVP Head of Global IR and ESG Mario Polywka - Interim CEO Laetitia Rouxel - CFO Matthias Evers - Chief Business Officer Craig Johnston - COO Cord Dohrmann - Chief Scientific Officer Conference Call Participants Charles Weston - RBC Capital Markets Thibault Boutherin - Morgan Stanley Michael Ryskin - Bank of America Peter Verdult - Citigroup Inc. Ben Jackson - Jefferies Falko Friedrichs - Deutsche Bank Joseph Hedden - Rx Securities Christian Ehmann - Warburg Research Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2024 Conference Call. I am Sandra, the chorus call operator.

Evotec SE (EVO) Q1 2024 Earnings Call Transcript

HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024

Chewy

Endava plc - ADR

Growth stocks have been huge winners over the past 18 months. Investors have shrugged off the sector's 2022 bust and returned to growth and technology names with great enthusiasm.

3 Growth Stocks to Buy at 52-Week Lows

Bayer AG

BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY BERLIN AND HAMBURG, GERMANY / ACCESSWIRE / April 30, 2024 / Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs). The collaboration aims to identify and validate novel targets, with the goal of building a portfolio of precision cardiology therapeutics by leveraging Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs).

Bayer and Evotec Collaborate to Advance Precision Cardiology

Evotec SE (EVO) Q4 2023 Earnings Call Transcript

Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts.

Evotec: Still A Speculative Buy After A Significant Decline

Evotec (NASDAQ: EVO ) stock is taking a beating on Wednesday following the release of the company's earnings report for the full year of 2023! Evotec is sliding lower today alongside the company's outlook for 2024.

Why Is Evotec (EVO) Stock Down 33% Today?

Shares of German biotech Evotec lost a third of their value on Wednesday on an uncertain outlook as it named a new chief executive.

Evotec shares lose a third of their value on cloudy outlook

FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST - EVOTEC BIOLOGICS” STARTING Q1 2024 HAMBURG, GERMANY / ACCESSWIRE / April 24, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond. CONTINUED GROWTH DESPITE MULTIPLE CHALLENGES Group revenues up 4% to € 781.4 m (+6% at constant fx rates (2022: € 751.4 m)) Revenues from Just - Evotec Biologics up 111% to € 108.4 m (2022: € 51.3 m) Base business excluding Just - Evotec Biologics down (4)%, including approx.

Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth

HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.

Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAMME HAMBURG, GERMANY AND SEATTLE, WA / ACCESSWIRE / April 18, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Fibrosis is characterised by marked and pathogenic build-up of the tissue matrix, leading to tissue degeneration in organs, including the liver and lungs.

Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAM HAMBURG, Germany and SEATTLE , April 18, 2024 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. The strategic partnership leverages Variant Bio's cutting-edge genomic discovery capabilities and VB-Inference platform.

EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective 15 June 2024. Aurélie will be joining Evotec's Management Board, bringing with her a wealth of experience and expertise in Human Resources leadership.

News for Evotec SE Stock (EVO)